Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04242953 · ClinicalTrials.gov registry record · Phase 1
Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects
A Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT04242953 is a Phase 1 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 140 participants.
The verdict
NCT04242953, a Phase 1 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
This is a Multipart Phase 1 Randomized, Double blind and Placebo controlled Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in healthy male and postmenopausal female volunteers.
Interventions
- DRUG matching placebo
- DRUG SCO-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2020-03-04 |
| Est. Completion | 2022-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04242953
The ClinicalTrials.gov registry entry for NCT04242953 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which matching placebo is the first listed.
NCT04242953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04242953 about?
NCT04242953 is a clinical study titled "Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects". This is a Multipart Phase 1 Randomized, Double blind and Placebo controlled Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in healthy male and postmenopausal female volunteers.
What is the current status of trial NCT04242953?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2020-03-04. Estimated completion is 2022-10-21.
What interventions are being tested in trial NCT04242953?
The interventions under investigation include: matching placebo (DRUG), SCO-120 (DRUG).
Who is sponsoring clinical trial NCT04242953?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.